



Response to ARM20 ([Request to reclassify Wasp-Eze Spray from P to GSL](#)) from the NPA.

Response of the National Pharmaceutical Association to ARM 20

Thank you for giving the National Pharmaceutical Association (NPA) the opportunity to comment on consultation letter ARM 20 on proposals to reclassify Wasp-Eze spray 30ml as a GSL product.

We wish to raise the following concerns regarding the proposed reclassification of this product.

Role of the pharmacist

When Wasp-Eze is supplied through a pharmacy the pharmacist and their staff will provide information to the patient that is important for the appropriate treatment of insect bites and stings. Patients need to be aware that if symptoms persist after using two applications of Wasp-Eze they should consult a pharmacist or practitioner. Wasp-Eze is only suitable for the immediate treatment of bites and stings, a later reaction to a bite or sting will require advice on suitable treatment from the pharmacist or their staff. In addition, pharmacists and their staff are alert to possible signs of an allergic or anaphylactic reaction to bites and stings and can refer patients for emergency medical treatment when necessary. Pharmacists and their staff would advise patients with lymph node enlargement, inflammation or signs of infection of the wound to visit their practitioner. Without the involvement of the pharmacist and their staff this advice is not available to the patient so clear information and warnings on the pack and PIL are required.

Specific GSL requirements

We agree that further contraindications and warnings should be introduced into the GSL product information, including sensitivity to any of the ingredients, use on eczematous or sunburnt skin: use on large areas of skin; use on the face. We also support the proposal that the GSL product will not be indicated for children less than 2 years of age and may not be supplied in pack sizes greater than 30ml.

Advertising and product information

We recommend further information should be included on the pack and patient information leaflet. All the advice that is available from the pharmacist, as listed above, should be included. There should be a clear recommendation to consult a pharmacist or practitioner if symptoms persist or worsen. Product information and advertisements must state that further advice is available from the pharmacist. Also, because of the issues outlined above, advertisements should contain a clear recommendation to read the product literature before use.

We hope you take our comments on board.